FDA Tracker newsroom · PCAC

The FDA advisory panel backed BPC-157, KPV, TB-500 and MOTS-c, here's what that does and doesn't mean.

Jul 23, 2026 · Last reviewed Jul 24, 2026

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500 and MOTS-c to the 503A Bulks List, against its own scientists' advice. A recommendation is not approval, not authorization, and not availability. Nothing you can buy changed. Verdict dots stay amber.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that four peptides, BPC-157 (reviewed for ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTS-c (obesity and osteoporosis), be added to the 503A Bulks List. The votes were close and split nearly evenly: 8–6 with one abstention for BPC-157, KPV and TB-500, and 7–5 with two abstentions for MOTS-c.

The recommendation runs against the FDA's own scientific staff, who had advised in the pre-meeting briefing against adding any of the peptides, citing gaps in characterization, little or no human clinical evidence, and safety questions. PCAC is an advisory committee: its recommendation informs the FDA, but the agency is not bound by it and has, at times, decided differently.

Here is the part the headlines miss. A favorable advisory vote is not FDA approval, it is not authorization to compound, and it does not place these peptides on the 503A Bulks List. Placement requires the FDA to run a formal rulemaking, a proposed rule, a public-comment period, then a final rule, a process that realistically takes twelve to eighteen months or more. Earliest legitimate access is late 2026 into 2027, and only if the FDA proceeds.

So our signals move exactly as they should: the regulatory pill advances from “Under PCAC review” to “PCAC recommended · rulemaking pending,” while the verdict dot stays amber, because you still cannot legitimately get these. The gap between the two signals is the honest read: the status genuinely advanced, and availability did not.

Day two (July 24) covers DSIP/Emideltide, Semax, and Epitalon. We will post that outcome the same day and will not pre-announce it, day one's pattern is suggestive, not binding.

What moved, and what did not

Regulatory status (BPC-157): Under PCAC review → PCAC recommended · rulemaking pending.

Plain-English verdict: unchanged (amber). A recommendation is not approval, not authorization to compound, and not availability — and a rejection does not move the dot either, because none of these was available before the vote.

Molecules in this update

• BPC-157 — FDA status
• KPV — FDA status
• TB-500 — FDA status
• MOTS-c — FDA status

Primary sources

• FDA July 23–24, 2026 PCAC meeting page
• FDA draft questions / voting agenda
• PCAC docket FDA-2025-N-6895 (regulations.gov)

Reviewed by the Peptós.LIFE clinical team · Medical & regulatory review.

Compounded medications are not FDA-approved. PCAC is an advisory committee: a favorable vote leads to FDA rulemaking, not authorization and not next-day availability. Nothing here is medical advice, and no peptide is offered for sale on this page.

Get the alert when this status actually changes · Full FDA status board · All regulatory updates